explore -WSS

explore

author：fashion 2025-09-03 14:43:02 - browse：8572

A medical device to treat below-the-knee chronic limb-threatening ischemia, Esprit BTK resorbable scaffold, is shown consisted of pieces of geometric shapes that lined up into a pipe on a blue background — health tech coverage from STAT — Cardiovascular doctors are optimistic about Abbott’s new below-knee stent that disappears into the blood vessel’s walls over the course of three years. Courtesy Abbott

An Abbott device that failed in heart disease patients is getting a new life in patients with severe vascular disease.

The device is a below-knee stent that widens clogged blood vessels, and then vanishes into the vessel’s walls over the course of three years. It also delivers a drug that prevents scar tissue from forming — a common risk factor with traditional metal stents that further narrow the vessel.

Abbott’s first dissolvable stent, for coronary artery disease, received Food and Drug Administration approval in 2016. But the company voluntarily pulled the product from the market just over a year later due to “low commercial uptake.” The device also received mixed results in clinical trials.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — and get additional analysis of the technologies disrupting health care — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： How to save PrEP access — and even expand it
Next article： FDA approves first new drug developed for postpartum depression

WSS

Xenotransplantation trials will require adjusting expectations, experts say

What to know about the judge who will handle the Trump case

Be careful with at

Altering the blood type of lungs raises potential for universal organs for transplants

Judge sides with young activists in first

Judge sides with young activists in first

focus

explore

This article is exclusive to STAT+ subscribers

Unlock this article — and get additional analysis of the technologies disrupting health care — by subscribing to STAT+.

entertainment

ChatGPT in medicine: STAT answers readers' burning questions

Maui wildfire now ranks as the fifth

Activists slam private health insurers over coverage restrictions

Inside the rise of 'mukbang' eating videos

Anesthesiologist group: stop taking Ozempic before surgery

Living organ donors deserve priority status for transplants

George Santos makes 1st court appearance after pleading not guilty to 13 counts

Over 1,300 arrested in France in 4th night of protests over fatal police shooting of teen Nahel M.

United colonoscopy coverage change 'may cost lives,' doctors say

Surge in Apellis stock fueled by confidence in safety of its eye drug

Wikipedia

A public health expert passes on football's full body collisions for youths

Mom launches Girl Scout troop for LGBTQ youth in Texas

Can medical device makers keep up in the race to treat obesity?

Hospitals are dialing back on venture capital investing

Living organ donors deserve priority status for transplants

Aspartame and sugar

focus

hotspot

focus

focus